Adaptive Clinical Trials Benefit Smaller Laboratories

This latest article in outsourcing-pharma.com highlights that according to research done by Pacific Biometrics (PBI), the use of adaptive clinical trials and biomarkers will benefit smaller laboratory services companies, even though has been generally detrimental to CROs. The use of biomarkers and adaptive clinical trials used together are completed quicker and use less money from a company's backlog.

PBI has been able to achieve a growth of five percent from revenues in 2008 to this year, and is expecting the same trend to continue in 2010. PBI executives believe that the changes in adaptive clinical trials have directly impacted the volume of work flowing through their laboratories.